GlassScriptPhysician profile
Victoria Dunaevsky
NPI 1922273929
$3,251.00
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2020: $95.60 · 2021: $159 · 2022: $938 · 2023: $1,250 · 2024: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,759.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,758.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $540.50 | 2022-2024 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $535.19 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $522.71 | 2019-2024 | Trelegy Ellipta, Shingrix, Flulaval Quadrivalent |
| Pfizer INC. | $267.57 | 2020-2024 | |
| Lilly USA, LLC | $263.77 | 2019-2024 | Mounjaro |
| Amgen INC. | $215.11 | 2019-2024 | Evenity, Prolia, Repatha |
| Astellas Pharma US INC | $99.78 | 2023-2024 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $88.46 | 2022-2024 | Farxiga, Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $85.94 | 2022-2024 | Gardasil 9, Vaxelis, M-M-R II |
| Bayer Healthcare Pharmaceuticals INC. | $74.39 | 2022-2024 | |
| Abbott Laboratories | $72.05 | 2022-2023 | Freestyle Libre 3 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $61.50 | 2023 | Lifevest |
| Medtronic, INC. | $48.94 | 2022 | |
| Phathom Pharmaceuticals, INC. | $47.80 | 2023-2024 | Voquezna |
| Edwards Lifesciences Corporation | $37.45 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $36.41 | 2021-2023 | Nexletol |
| Novartis Pharmaceuticals Corporation | $32.81 | 2019-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.72 | 2022 | |
| Genzyme Corporation | $23.94 | 2022 | |
| Amarin Pharma, INC. | $23.63 | 2021 | |
| Sanofi-Aventis U.S. LLC | $22.80 | 2019 | |
| Xeris Pharmaceuticals, INC. | $22.76 | 2024 | Gvoke Hypopen |
| Sanofi Pasteur INC. | $19.54 | 2022 | |
| Corium, LLC | $17.94 | 2022 | |
| Dynavax Technologies Corporation | $16.57 | 2022 | |
| Dexcom, INC. | $15.58 | 2023 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.90 | 2020 | |
| Pulmonx Corporation | $13.24 | 2023 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Dunaevsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.